CaMKII in sinoatrial node physiology and dysfunction by Yuejin Wu & Mark E. Anderson
REVIEW ARTICLE
published: 18 March 2014
doi: 10.3389/fphar.2014.00048
CaMKII in sinoatrial node physiology and dysfunction
YuejinWu1 and Mark E. Anderson1,2*
1 Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA, USA
2 Department of Molecular Physiology and Biophysics, Carver College of Medicine, University of Iowa, Iowa City, IA, USA
Edited by:
Donald M. Bers, University of
California, Davis, USA
Reviewed by:
Zhandi Liao, University of California,
Davis, USA
Satoshi Matsuoka, University of
Fukui, Japan
*Correspondence:
Mark E. Anderson, Department of
Internal Medicine and Department of
Molecular Physiology and Biophysics,
Carver College of Medicine,
University of Iowa, Iowa City,
IA 52242, USA
e-mail: mark-e-anderson@uiowa.edu
The calcium and calmodulin-dependent protein kinase II (CaMKII) is present in sinoatrial
node (SAN) pacemaker cells and is required for physiological “ﬁght or ﬂight” SAN beating
rate responses. Inhibition of CaMKII in SAN does not affect baseline heart rate, but reduces
heart rate increases in response to physiological stress. CaMKII senses intracellular
calcium (Ca2+) changes, oxidation status, and hyperglycemia to phosphorylate substrates
that regulate Ca2+-sensitive proteins, such as L-type Ca2+ channels, phospholamban,
and cardiac ryanodine receptors (RyR2). All of these substrates are involved in the
SAN pacemaking mechanism. Excessive CaMKII activity, as occurs under pathological
conditions such as heart failure, ischemia, and diabetes, can promote intracellular Ca2+
overload and reactive oxygen species production. Oxidation of CaMKII (ox-CaMKII) locks
CaMKII into a constitutively active conﬁguration that contributes to SAN cell apoptosis
and ﬁbrosis. This ox-CaMKII-mediated loss of functional SAN cells contributes to SAN
dysfunction (SND) and sudden death. Thus, CaMKII has emerged as a central regulator
of physiological SAN responses and a key determinant of SND.
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INTRODUCTION
The sinoatrial node (SAN) is a specialized region of heart tis-
sue present at the junction of the right atrium and superior vena
cava that extends along the cristae terminalis, where it initiates
each normal heart beat. The pacemaking function of SAN cells
is accomplished by generation of spontaneous action potentials.
There appear to be redundant systems in SAN for generating
spontaneous cell membrane potential depolarizations, which are
ultimately necessary to sustain life by maintaining cardiac output.
One of these systems comprises a set of cell membrane delimited
ion channels. These ion channels include hyperpolarization-
activated cyclic nucleotide-gated (HCN) channels that conduct an
inward current, sometimes called a pacemaker current or funny
current (If ; DiFrancesco, 1991), L-type (CaV1.2/1.3; Christel et al.,
2012) and T-type (CaV3.1/3.2) Ca2+ channels (Mangoni et al.,
2006; Tanaka et al., 2008; Brahmajothi et al., 2010) and several
K+ channels, including ERG (Brahmajothi et al., 1997, 2010) and
KvLQT1 (Chandler et al., 2009; Brahmajothi et al., 2010 ). All of
these ion channels have the potential to play a role in pacemaking
under different conditions. The other system involves intracellular
Ca2+ machinery that is used for excitation–contraction coupling
in mechanically purposed myocardium, but that contributes to
rhythmic intracellular Ca2+ oscillations in SAN. This system
enables SAN ﬁght or ﬂight heart rate increases and contributes
to SAN cell death under pathological stress. These components
include the sarcoplasmic reticulum (SR; Rigg and Terrar, 1996),
which contains the sarco/endoplasmic reticulum Ca2+-ATPase
(SERCA2a), the ryanodine receptor 2 (RYR2), a large Ca2+ chan-
nel that releases Ca2+ from the SR lumen to the cytoplasm and the
cell membrane spanning Na+/Ca2+ exchanger (NCX1; Sanders
et al., 2006). The components in both systems collaborate but are
also capable of independent activity that ensures nonstop pace-
making activity (Lakatta and DiFrancesco, 2009; Lakatta et al.,
2010).
We believe that the effects of the multifunctional Ca2+ and
calmodulin-dependent protein kinase II (CaMKII) on SAN cell
biology are related to actions on Ca2+ homeostasis. CaMKII is
a multifunctional serine/threonine-speciﬁc protein kinase that
is initially activated by the Ca2+/calmodulin complex (Schul-
man and Greengard, 1978). CaMKII is present in contracting
myocardium and in SAN cells (Vinogradova et al., 2000). Details
of CaMKII structure, function, activation, and inactivation are
contained in another chapter in this compendium (XYZ). How-
ever, the CaMKII holomeric structure allows it to perform as
a precisely regulated enzyme that activates and inactivates with
Ca2+/calmodulin binding and unbinding but also to transition
into a constitutively active conformation by post-translational
modiﬁcations to the autoregulatory domain (Kuret and Schul-
man, 1985; Erickson et al., 2008, 2013; Chao et al., 2011; Gutierrez
et al., 2013). Excessive levels of constitutively active CaMKII are
linked to cardiovascular and pulmonary diseases, including SAN
dysfunction (SND; Erickson et al., 2011; Sanders et al., 2013).
CaMKII IN SAN PHYSIOLOGY
Activated CaMKII can catalyze phosphorylation of multiple Ca2+
homeostatic proteins, including L-type, e.g., CaV1.2 (Dzhura et al.,
2000; Grueter et al., 2006) and T-type, e.g., CaV3.2 (Yao et al.,
2006) Ca2+ channels, phospholamban (PLN; Lindemann et al.,
1983), a protein that negatively regulates SERCA2a in the absence
of CaMKII or protein kinaseA catalyzed phosphorylation (Kranias
and Hajjar, 2012), and RYR2 (Witcher et al., 1991; Wehrens et al.,
2004). CaMKII catalyzed phosphorylation increases Ca2+ entry
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through Ca2+ channels, increases SERCA2a uptake of cytoplasmic
Ca2+ into the SR lumen through phosphorylating PLN, which in
turn increases the pool of SR releasable Ca2+, increases Ca2+
release from RYR2 by phosphorylation of RYR2 at several sites,
including serine 2814. On one hand, these effects will increase
intracellular Ca2+ ﬂux through the SR and RYR2 to accelerate
NCX1 to increase SAN cell action potential frequency and the
physiological ﬁght or ﬂight heart rate response. On the other hand,
excessive CaMKII activity will cause Ca2+ overload (Wagner et al.,
2011), which can induce increased reactive oxygen species (ROS)
production and cause SAN cell damage or death (Swaminathan
et al., 2011; Luo et al., 2013).
The role of CaMKII in SAN function has been explored since
1989 (Hagiwara and Irisawa, 1989). The major focus of this study
was on the effects of calmodulin or CaMKII on If currents by
using calmidazolium, a calmodulin inhibitor with many off tar-
get actions (Klöckner and Isenberg, 1987). They found that If
currents were sensitive to intracellular Ca2+ but no evidence
that If was regulated by CaMKII. A more recent study (Rigg
et al., 2003) conﬁrmed that If currents are regulated by Ca
2+ and
calmodulin but not by the CaMKII pathway. They showed that If
current amplitude was unaffected by the CaMKII inhibitor KN-
93 (1 μM) although this CaMKII inhibition did reduce L-type
Ca2+ current by 48 ± 19% at 0 mV voltage clamp command
potential. However, a more recent study challenged the concept
of calmodulin regulation of If (Chatelier et al., 2005) based on
experiments in inside-out cell membrane macro-patches excised
from rabbit SAN cells. They found that “intracellular” calmod-
ulin perfusion had no effect on HCN activity and did not change
the cAMP-induced If activation shift. This study suggested that
another calmodulin inhibitor,W-7, with well documented off tar-
get actions had direct effects on If that were independent of Ca
2+
and calmodulin. The myriad off target actions on ion channels
represent major obstacles to the use of CaMKII inhibitors in func-
tional studies ( Ledoux et al., 1999; Gao et al., 2006; Rezazadeh
et al., 2006; Liao et al., 2011). CaMKII enhances CaV1.2 chan-
nel currents in ventricular myocytes (Anderson et al., 1994; Xiao
et al., 1994; Yuan and Bers, 1994) and so could potentially affect
SAN automaticity by actions on CaV1.2. A paper from the Xiao
group showed that CaMKII was likely to play an important role
in SAN pacemaker activity by actions at voltage-gated Ca2+ chan-
nels (Vinogradova et al., 2000). They were able to stop SAN cell
automaticity by using CaMKII inhibitors KN-93 or myristoylated
autocamtide-2-related inhibitory peptide (AIP) (a cell membrane
permeant peptide inhibitor modeled after the CaMKII autoin-
hibitory region). The ﬁndings from the Xiao group supported
an If -independent role for cardiac pacing. However, these stud-
ies were mostly performed using small molecule inhibitors with
off target actions that complicate interpretation of the results.
Taken together, these ﬁndings highlight some of the limitations
of available small molecule calmodulin and CaMKII antagonists
and suggest that If is not directly responsive to calmodulin or
CaMKII but leave open the question whether CaMKII actions at
CaV1.2 channels contribute to SAN automaticity. We developed
a mouse with myocardial targeted transgenic expression of AC3-
I, a highly selective CaMKII inhibitory peptide, under control of
the α-myosin heavy chain promoter (Zhang et al., 2005). AC3-I
expression was present in SAN cells and a study from our group
using thismouse found thatCaMKII inhibitiondidnot affect base-
line SAN pacemaking activity but selectively impaired the ﬁght or
ﬂight response of SAN cells to isoproterenol (Wu et al., 2009).
CaMKII was responsible for approximately half of the dynamic
heart rate response range. We found that neither SAN cell Ca2+
channels nor If currents fromAC3-Imicewere different compared
with their WT littermates nor control transgenic mice express-
ing AC3-C, an AC3-I like peptide without biological activity. We
found that SR Ca2+ content responses to isoproterenol in those
mice were reduced, potentially as a consequence of diminished
CaMKII catalyzed phosphorylation of PLN. The reduced SR Ca2+
content likely contributed to reduced Ca2+ spark frequency as
well as decreased Ca2+ release from SR (Figure 1). Our ﬁnd-
ings were later conﬁrmed by studies from another group using
a CaMKIIδ knock out mouse (Xu et al., 2010). Their study also
showed that CaMKII is required for heart rate increases by isopro-
terenol stimulation or in response to a physiological ﬁght or ﬂight
mechanism. A recent study from Terrar group (Collins and Ter-
rar, 2012) suggested that the effect of CaMKII in atrial myocytes
may be primarily on SR proteins due to different distribution
of CaMKII in ventricular myocytes compare to atrial myocytes
which lack of T-tube. The effects of CaMKII on atrial Ca2+ chan-
nels are indirectly through CaMKII enhanced SR Ca2+ releasee
that stimulates adenylyl cyclases (ACs). Recently, one study from
Lakatta group using KN-93, myristoylated AIP, and W-7 to inhibit
CaMKII (Yaniv et al., 2013) suggest that CaMKII may affect SAN
automaticity by actions on metabolism. In our opinion, these
results are intriguing but inconclusive because of the documented
off-target actions of these reagents (Ledoux et al., 1999; Chate-
lier et al., 2005; Gao et al., 2006; Rezazadeh et al., 2006; Liao et al.,
2011). Taken together, these studies support a view that CaMKII is
not required to maintain basal heart rates but plays a critical role
in sustained heart rate increases during physiological stress. This
selective role of CaMKII on heart rate suggests that CaMKII inhi-
bition could protect against excessive heart rates without reducing
baseline heart rate.
CaMKII IN SND
Conditions that favor SND, such as heart failure, atrial ﬁbril-
lation (AF), and advanced age are marked by heightened ROS
(Cesselli et al., 2001; Kim et al., 2005; Dai et al., 2009). Because
CaMKII is activated by ROS (Erickson et al., 2008) in the setting
of increased angiotensin II (Ang II), a circulating neurohormone
present at increased levels in heart failure, we tested if oxidized
CaMKII (ox-CaMKII) could contribute to SND. We found Ang
II increased atrial and SAN oxidation by activating NADPH oxi-
dase, leading to increased ox-CaMKII, SAN cell apoptosis, and
SND (Swaminathan et al., 2011). In order to test whether ele-
vated ox-CaMKII could cause SND, mice were infused with Ang
II. Ang II infusion for 3 weeks caused increased SAN ox-CaMKII,
SAN cell apoptosis, ﬁbrosis, slowed atrial impulse conduction
velocity, and SND. Ang II-triggered SND was prevented by trans-
genic myocardial and SAN cell expression of AC3-I (Zhang
et al., 2005) and by SAN-targeted gene therapy (Kikuchi et al.,
2005) providing ectopic SAN expression of a CaMKII inhibitory
peptide, CaMKIIN, that is endogenous to neurons but absent in
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FIGURE 1 | Mechanism of CaMKII effects on Fight or Flight in SA node.
(A) Fight or ﬂight stimulation (e.g., isoproterenol) activates PKA and CaMKII,
which phosphorylate L-type Ca2+ channels and PLN to increase SR Ca2+
content. RYR2 phosphorylation increases Ca2+ release from SR. Increased
Ca2+ release accelerates NCX1 activity which increases the diastolic
depolarization rate (DDR) of SAN action potentials (B). SR Ca2+ content
increases by isoproterenol are abolished by CaMKII inhibition. Upper panel
shows DDR change with isoproterenol (red trace) compare to control DDR
(black trace), MDP, maximal diastolic potential. Middle panel shows Ca2+
spark frequency increases after isoproterenol are abolished by CaMKII
inhibition. The lower panel shows the heart rate increase by isoproterenol
is abolished by CaMKII inhibition. All shaded bars in bar graphs represent
data with isoproterenol effects. Both white bars (WT control) and black bars
(transgenic control) represent data from control SAN. *p < 0.05,
***p < 0.001 before vs. after isoproterenol, † p < 0.05 compare to control
SAN groups, †† or ‡ p < 0.01 compare to control SAN groups.
heart (Chang et al., 1998). Neither transgenic nor gene-targeting
approaches to SAN CaMKII inhibition affected the hypertensive
response to Ang II, nor did they abrogate the increased SAN
ROS due to Ang II infusion, indicating that CaMKII was a crit-
ical downstream signal for the pathological actions of ROS on
SAN. The increase in SAN ox-CaMKII by Ang II required acti-
vation of NADPH oxidase, because it was absent in p47−/−
mice (Huang et al., 2000) lacking functional NADPH oxidase. We
developed a structural and computational model of the SAN that
revealed a quantitative mechanism to explain how Ang II-induced
SAN cell apoptosis resulted in SND by reducing SAN cell num-
ber and increasing electrotonic loading of surviving SAN cells
to cause loss of high-ﬁdelity impulse formation and propagation
(Figure 2; Huke and Knollmann, 2011). We also found that right
atrial tissue from patients with heart failure who required artiﬁcial
pacemakers for SND or dogs with pacing-induced heart failure
and SND had elevated ox-CaMKII compared with patients with
heart failure alone or dogs with non-SND controls. These ﬁnd-
ings provide insights into how excessive activation of CaMKII
in SAN cells causes SND, suggest ox-CaMKII is a biomarker
for SND and identify what we believe to be a novel candidate
approach to preventing SND in high risk settings by CaMKII
inhibition.
Patients with AF are at increased risk for SND (Chang et al.,
2013) and CaMKII activity and expression are increased in ﬁb-
rillating human atria (Neef et al., 2010). We recently found that
ox-CaMKII is increased inﬁbrillating compared tonon-ﬁbrillating
human atria and that Ang II infusion increases AF induction in
mice (Purohit et al., 2013). Mice with transgenic expression of
AC3-I, mice with a knock-in mutation (MM-VV) in CaMKIIδ
that prevents oxidative activation and mice with transgenic over-
expression of methionine sulfoxide reductase A that reverses the
ﬁrst oxidation state (sulfoxide) of methionine were all resistant
to Ang II-induced AF. We interpret these ﬁndings to suggest that
ox-CaMKII is a unifying signal for SND and AF.
Diabetes is a risk factor for SND (Podlaha and Falk, 1992).
We recently found signiﬁcantly more ox-CaMKII in right atrium
from patients with a history of diabetes and myocardial infarction
(MI) compared with right atrial tissue from patients with MI but
no diabetes, suggesting that ox-CaMKII could contribute to the
increased mortality in diabetic patients after MI (Luo et al., 2013).
Streptozotocin (STZ)-treated mice develop severe type I diabetes
due to death of pancreatic β-cells. STZ-treated diabetic mice were
twice as likely to die after MI surgery as vehicle-treated control
mice, mimicking the increased mortality in diabetic patients com-
pared with that in non-diabetic patients after MI. STZ-treated
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FIGURE 2 | Mechanism of Ang II-induced SND. Normally, the small volume
of excited tissue in the SAN (source) depolarizes the neighboring quiescent
atrial tissue (sink). In conditions with increased Ang II, NADPH oxidase is
activated, leading to oxidation of two methionine residues of CaMKII,
rendering the enzyme autonomously active. Elevated activity of CaMKII leads
to SAN cell death, reducing the threshold volume of automatic cells of the
SAN and increasing non-excitable tissue in the form of ﬁbrosis. This increased
electrotonic loading produces a source-sink mismatch slows the beating rate,
and causes SND. CT, crista terminalis; IAS, inferior atrial septum. Reproduced
from Huke and Knollmann (2011), with permission from JCI.
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MM-VV mice and mice with transgenic myocardial and SAN
expression of AC3-I (Zhang et al., 2005) were protected from
increased mortality after MI, indicating that increased ox-CaMKII
was essential for excess mortality after MI in STZ-treated mice.
Death in STZ-treated mice after MI was due to severe bradycar-
dia, consistent with known defects in cardiac pacemaker function
in another diabetic animal model (Howarth et al., 2007). In con-
trast to our earlier studies with Ang II-triggered ROS by activation
of NADPH oxidase (Swaminathan et al., 2011), we found that
hyperglycemia-induced ROS were primarily from mitochondria.
Excess mortality in STZ-treated diabetic mice after MI surgery
was prevented by chronic infusion with a mitochondrial targeted
antioxidant, Mito-TEMPO. Mito-TEMPO reduced ox-CaMKII,
preservedheart rates, and improved survival afterMI.These results
provide new evidence that ox-CaMKII is a biomarker for SND
and suggest that mitochondrial or CaMKII-targeted antioxidant
therapies could beneﬁt high-risk diabetic patients.
In summary, CaMKII appears to play important roles in tun-
ing the ﬁght or ﬂight response and in promoting SND. It may be
that the physiological beneﬁts of CaMKII activation in early life
are outweighed in later life by the tendency of CaMKII to become
persistently active under conditions of high oxidative, neurohu-
moral and hyperglycemic stress. The tractability of CaMKII as a
target for selectively controlling heart rate and preventing SND
will depend upon the availability of clinically suitable CaMKII
inhibitory drugs or gene therapy.
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